Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Hahn, Deirdre ^a   Esezobor, Christopher I ^b   Elserafy, Noha ^a   Webster, Angela C ^c,d,e   Hodson, Elisabeth M ^c,e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF LAGOS   (Nigeria)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008453575     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011690     Document Type: Article

References (33)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Archives of Internal Medicine 2002;162(2):1401-8. [MEDLINE: 12076240]
2. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. Journal of the American Society of Nephrology 2010;21(12):2151-6. [MEDLINE: 21115615]
3. Anonymous Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990;300(6724):573-8. [MEDLINE: 2108751]
4. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clinical Nephrology 1990;34(6):272-8. [MEDLINE: 2073771]
5. Cody JD, Daly C, Campbell MK, Khan I, Rabindranath KS, Vale L, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2]
6. Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology 2013;14:24. [MEDLINE: 23351270]
7. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;355(20):2071-84. [MEDLINE: 17108342]
8. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 1987;316(2):73-8. [MEDLINE: 3537801]
9. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney International 2004;66(2):753-60. [MEDLINE: 15253730]
10. Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD003895.pub3]
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
12. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
13. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology 2002;13(2):504-10. [MEDLINE: 11805181]
14. KDIGO KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International - Supplement 2012;2(4):1-64.
15. Koch KM, Frei U. Treatment of renal anemia, 1960-1990. Advances in Nephrology From the Necker Hospital 1991;20:19-30. [MEDLINE: 2063711]
16. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proceedings of the National Academy of Sciences of the United States of America 1985;82(22):7580-4. [MEDLINE: 3865178]
17. Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist 2011;16 Suppl 3:19-24. [MEDLINE: 21930831]
18. Lundin AP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Seminars in Nephrology 1989;9(1 Suppl 1):22-9. [MEDLINE: 2648517]
19. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of American Society of Nephrology 1999;10(11):2392-5. [MEDLINE: 10541299]
20. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Current Hematology Reports 2005;4(6):436-40. [MEDLINE: 16232379]
21. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta analysis: erythropoiesis stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine 2010;153(1):23-33. [MEDLINE: 20439566]
22. Palmer SC, Nand K, Dwi Nur Hidayati L, Munasinghe A, Nelson C, Khafaji MM, et al. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009904]
23. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD010590.pub2]
24. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippolli GF. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD009297.pub2]
25. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovascular Drugs & Therapy 2008;22(1):37-44. [MEDLINE: 18095148]
26. Ritz E, Eisenhacht A. Early epoetin treatment in patients with renal insufficiency. Nephrology Dialysis Transplantation 2000;15 Suppl 3:40-4. [MEDLINE: 11032357]
27. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. American Journal of Kidney Diseases 1994;24(5):777-84. [MEDLINE: 7977319]
28. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 2006;355(20):2085-98. [MEDLINE: 17108343]
29. Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ, et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. American Journal of the Medical Sciences 1988;296(3):171-9. [MEDLINE: 3177433]
30. Strippoli GF, Navaneethan SD, Craig JC, Palmer SC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003967.pub2]
31. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. World Health Organization. 2011. www.who.int/vmnis/indicators/haemoglobin/en/ (accessed 10 May 2015). [: WHO/NMH/NHD/MNM/11.1]
32. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2(8157):1175-8. [MEDLINE: 2877323]
33. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. American Journal of Kidney Diseases 1989;14(6):478-85. [MEDLINE: 2596475]